

# Yu-Yun Shao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1117279/publications.pdf>

Version: 2024-02-01

122  
papers

2,195  
citations

201674

27  
h-index

276875

41  
g-index

124  
all docs

124  
docs citations

124  
times ranked

3478  
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study. <i>BMC Cancer</i> , 2022, 22, 55.	2.6	14
2	Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2022, 126, 1806-1814.	6.4	11
3	ICOS-Positive Regulatory T Cells in Hepatocellular Carcinoma: The Perspective from Digital Pathology Analysis. <i>Oncology</i> , 2022, 100, 419-428.	1.9	1
4	Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 559-566.	1.7	24
5	It takes two to tango: breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockade. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 1-4.	1.7	8
6	Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 1051-1060.	1.7	72
7	Reply to letter to the editor: Low skeletal muscle mass are predictive factors of survival for advanced hepatocellular carcinoma. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 781-782.	1.7	1
8	Solving the deficit of cancer pain management skills by education programs. <i>Supportive Care in Cancer</i> , 2021, 29, 1843-1848.	2.2	2
9	Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 144-150.	1.4	8
10	An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2021, 26, 422-426.	3.7	8
11	Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma. <i>Diagnostics</i> , 2021, 11, 1340.	2.6	6
12	Eg5 as a Prognostic Biomarker and Potential Therapeutic Target for Hepatocellular Carcinoma. <i>Cells</i> , 2021, 10, 1698.	4.1	5
13	An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 809-822.	3.7	17
14	Impact of expanded strong opioid availability on opioid prescription patterns in patients with cancer: A population-wide cohort study in Taiwan. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 16, 100255.	2.9	5
15	Limited Predictive or Prognostic Role of Tumor-Infiltrating Tissue-Resident Memory CD8 T Cells in Patients with Hepatocellular Carcinoma Receiving Immunotherapy. <i>Cancers</i> , 2021, 13, 5142.	3.7	2
16	Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials. <i>Cancers</i> , 2021, 13, 4962.	3.7	3
17	Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12880.	4.1	15
18	Satisfaction with pain management and impact of pain on quality of life in cancer patients. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e91-e98.	1.1	10

#	ARTICLE	IF	CITATIONS
19	The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma. <i>Journal of the Formosan Medical Association</i> , 2020, 120, 1581-1590.	1.7	4
20	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy. <i>Oncologist</i> , 2020, 25, e1280-e1285.	3.7	14
21	Abstract 1590: High ICOS/FOXP3 Tregs content in the tumor microenvironment is associated with poorer survival in patients with hepatocellular carcinoma. , 2020, , .		0
22	Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment. <i>Liver Cancer</i> , 2019, 8, 110-120.	7.7	46
23	Patients with head and neck cancer may need more intensive pain management to maintain daily functioning: a multi-center study. <i>Supportive Care in Cancer</i> , 2019, 27, 1663-1672.	2.2	8
24	Early alpha-fetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma. <i>Liver International</i> , 2019, 39, 2184-2189.	3.9	55
25	Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 480-490.	7.7	57
26	Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors. <i>Anticancer Research</i> , 2019, 39, 5675-5682.	1.1	30
27	Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 1433.	3.7	13
28	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 615-621.	3.0	5
29	A nationwide survey of adherence to analgesic drugs among cancer patients in Taiwan: prevalence, determinants, and impact on quality of life. <i>Supportive Care in Cancer</i> , 2019, 27, 2857-2867.	2.2	13
30	Understanding transdermal buprenorphine and a practical guide to its use for chronic cancer and non-cancer pain management. <i>Journal of Opioid Management</i> , 2019, 15, 147-158.	0.5	3
31	Abstract 4964: Associations between hepatitis etiology and immune cell infiltration in or around hepatocellular carcinoma. , 2019, , .		0
32	Abstract 4964: Associations between hepatitis etiology and immune cell infiltration in or around hepatocellular carcinoma. , 2019, , .		0
33	Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS/MS. <i>Analytica Chimica Acta</i> , 2018, 1019, 93-102.	5.4	50
34	A Phase I Study of S-1-based Concurrent Chemoradiotherapy Followed by Gemcitabine and S-1 in Metastatic Pancreatic Adenocarcinoma. <i>Anticancer Research</i> , 2018, 38, 4805-4812.	1.1	3
35	Successful Hepatic Arterial Infusion of Chemotherapy in a Patient with Advanced Hepatocellular Carcinoma and Impending Liver Failure. <i>Liver Cancer</i> , 2018, 7, 205-208.	7.7	4
36	Abstract 3627: Organ-specific differential responses to immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
37	Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC). <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 421-429.	2.3	19
38	National Policies Fostering Hospice Care Increased Hospice Utilization and Reduced the Invasiveness of End-of-Life Care for Cancer Patients. <i>Oncologist</i> , 2017, 22, 843-849.	3.7	19
39	Impact of Undertreatment of Cancer Pain With Analgesic Drugs on Patient Outcomes: A Nationwide Survey of Outpatient Cancer Patient Care in Taiwan. <i>Journal of Pain and Symptom Management</i> , 2017, 54, 55-65.e1.	1.2	25
40	P3.07-009 Use of Adjuvant Chemotherapy for Non-Small Cell Lung Cancer: The Real-World Clinical Practice in Taiwan. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1435-S1436.	1.1	0
41	Right or left? Side selection for a totally implantable vascular access device: a randomised observational study. <i>British Journal of Cancer</i> , 2017, 117, 932-937.	6.4	13
42	Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 722-730.	3.7	12
43	Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancer. <i>Supportive Care in Cancer</i> , 2017, 25, 533-539.	2.2	12
44	High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 949-953.	1.3	37
45	Using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to predict efficacy of axitinib for treatment of advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, e15656-e15656.	1.6	1
46	Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cells. <i>Oncotarget</i> , 2017, 8, 86681-86692.	1.8	11
47	Prescription Patterns of Sorafenib and Outcomes of Patients with Advanced Hepatocellular Carcinoma: A National Population Study. <i>Anticancer Research</i> , 2017, 37, 2593-2599.	1.1	17
48	Irinotecan and Oxaliplatin Might Provide Equal Benefit as Adjuvant Chemotherapy for Patients with Resectable Synchronous Colon Cancer and Liver-confined Metastases: A Nationwide Database Study. <i>Anticancer Research</i> , 2017, 37, 7095-7104.	1.1	6
49	Comparison of irinotecan and oxaliplatin as adjuvant chemotherapy for patients with resectable synchronous colon cancer plus liver-confined metastases: A retrospective nationwide database study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 624-624.	1.6	0
50	Abstract 80: Pooled shRNA screening using mouse xenografts of human hepatocellular carcinoma cells identifies CDK5 as a potential mechanism mediating sorafenib resistance. , 2017, , .		1
51	Abstract 4728: Plasma interleukin-6 level predicts prognosis of patients who received sorafenib for advanced hepatocellular carcinoma. , 2017, , .		0
52	Abstract 1636: Increased expression of programmed death-ligand 1 (PD-L1) on infiltrating immune cells of hepatocellular carcinoma (HCC) tissues after sorafenib treatment. , 2017, , .		0
53	Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice. <i>Journal of Cancer</i> , 2016, 7, 1515-1523.	2.5	9
54	Influence of age on opioid prescription of patients with advanced lung cancer. <i>Annals of Oncology</i> , 2016, 27, vi457.	1.2	0

#	ARTICLE	IF	CITATIONS
55	Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study. <i>BMC Cancer</i> , 2016, 16, 327.	2.6	42
56	Inhibition of the Wnt/ $\beta$ -catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma. <i>Cancer Letters</i> , 2016, 381, 58-66.	7.2	39
57	Key opioid prescription concerns in cancer patients: A nationwide study. <i>Acta Anaesthesiologica Taiwanica</i> , 2016, 54, 51-56.	1.0	9
58	Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1336-1341.	2.8	25
59	Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression. <i>Clinical Cancer Research</i> , 2016, 22, 2555-2564.	7.0	42
60	Effect of national policy changes on hospice utilization and the invasiveness of end-of-life care in cancer patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10008-10008.	1.6	1
61	Abstract 2831: Composite cyclin dependent kinase inhibition shows potent activity against hepatocellular carcinoma. , 2016, , .		0
62	High Serum Transforming Growth Factor- $\beta$ 1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib. <i>Clinical Cancer Research</i> , 2015, 21, 3678-3684.	7.0	76
63	Comparative Effectiveness of First-Line Platinum-Based Chemotherapy Regimens for Advanced Lung Squamous Cell Carcinoma. <i>Clinical Lung Cancer</i> , 2015, 16, 137-143.	2.6	14
64	Treatment Efficacy Differences of Sorafenib for Advanced Hepatocellular Carcinoma: A Meta-Analysis of Randomized Clinical Trials. <i>Oncology</i> , 2015, 88, 345-352.	1.9	31
65	Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan. <i>Clinical Colorectal Cancer</i> , 2015, 14, 177-184.e4.	2.3	36
66	Integrated Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) and Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) Quantitative Proteomic Analysis Identifies Galectin-1 as a Potential Biomarker for Predicting Sorafenib Resistance in Liver Cancer*. <i>Molecular and Cellular Proteomics</i> , 2015, 14, 1527-1545.	3.8	71
67	Young patients with colorectal cancer have increased risk of second primary cancers. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 1029-1035.	1.3	11
68	The Prognostic Impact of Type 2 Diabetes Mellitus on Early Cervical Cancer in Asia. <i>Oncologist</i> , 2015, 20, 1051-1057.	3.7	13
69	Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?. <i>World Journal of Gastroenterology</i> , 2015, 21, 10336.	3.3	38
70	Tumor c-Met expression and prognosis of advanced hepatocellular carcinoma patients treated with sorafenib.. <i>Journal of Clinical Oncology</i> , 2015, 33, 317-317.	1.6	0
71	Abstract 5421: HER3 inhibition has little efficacy on hepatocellular carcinoma cell lines. , 2015, , .		0
72	Abstract 5336: Improved antitumor effect of combining WNT/beta-catenin inhibition with sorafenib in hepatocellular carcinoma. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
73	Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives. <i>Journal of Hepatocellular Carcinoma</i> , 2014, 1, 85.	3.7	17
74	Type 2 Diabetes Mellitus Is Associated With Increased Mortality in Chinese Patients Receiving Curative Surgery for Colon Cancer. <i>Oncologist</i> , 2014, 19, 951-958.	3.7	24
75	β-Catenin (CTNNB1) Mutations Are Not Associated with Prognosis in Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2014, 87, 159-166.	1.9	35
76	Long-term disease-free survival achieved by anti-angiogenic therapy plus surgery in a hepatocellular carcinoma patient with extensive liver involvement and lung metastases. <i>Journal of the Formosan Medical Association</i> , 2014, 113, 577-578.	1.7	4
77	Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy. <i>Journal of Hepatology</i> , 2014, 60, 313-318.	3.7	47
78	Clinical Activity of Metronomic Chemotherapy in Liver Cancers. , 2014, , 189-202.		0
79	Phase Ib study of RO5137382/GC33 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) (NCT00976170).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4100-4100.	1.6	0
80	Risk of second primary malignancies in young patients with colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e14533-e14533.	1.6	0
81	The impact of diabetes mellitus on early cervical cancer in Asia: A population-based cohort study.. <i>Journal of Clinical Oncology</i> , 2014, 32, e16501-e16501.	1.6	0
82	Abstract 2865: High serum transforming growth factor β1 levels associated with poor survivals in patients with advanced hepatocellular carcinoma. , 2014, , .		0
83	Abstract 17: Hepatitis C virus (HCV) core protein potentiates proangiogenic activity of hepatocellular carcinoma (HCC) cells. <i>Cancer Research</i> , 2014, 74, 17-17.	0.9	1
84	Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy. <i>Anticancer Research</i> , 2014, 34, 1047-52.	1.1	8
85	Clinical Trials in Hepatocellular Carcinoma: An Update. <i>Liver Cancer</i> , 2013, 2, 345-364.	7.7	58
86	Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2013, 49, 106-114.	2.8	20
87	Predictive Biomarkers of Antiangiogenic Therapy for Advanced Hepatocellular Carcinoma: Where Are We?. <i>Liver Cancer</i> , 2013, 2, 93-107.	7.7	35
88	Modern Prospection for Hepatic Arterial Infusion Chemotherapy in Malignancies with Liver Metastases. <i>International Journal of Hepatology</i> , 2013, 2013, 1-11.	1.1	5
89	A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy. <i>Liver International</i> , 2013, 33, 1413-1419.	3.9	15
90	Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma. <i>Cancer</i> , 2013, 119, 1210-1216.	4.1	13

#	ARTICLE	IF	CITATIONS
91	Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study. <i>Oncology</i> , 2013, 85, 44-52.	1.9	46
92	The Germline BIM Deletion Polymorphism Is Not Associated with the Treatment Efficacy of Sorafenib in Patients with Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2013, 85, 312-316.	1.9	6
93	Radiofrequency Ablation Is Superior to Ethanol Injection in Early-Stage Hepatocellular Carcinoma Irrespective of Tumor Size. <i>PLoS ONE</i> , 2013, 8, e80276.	2.5	23
94	Unique histopathologic features of brain metastases from hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 169-169.	1.6	0
95	Association of diabetes mellitus with increased mortality in patients receiving curative surgery for colon cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 399-399.	1.6	0
96	Abstract 3547: The BIM deletion polymorphism not associated with treatment efficacy of sorafenib for advanced hepatocellular carcinoma.. , 2013, , .		0
97	Abstract 2052: WNT/beta-catenin signaling inhibitors improve the anti-proliferative effect of sorafenib against hepatocellular carcinoma (HCC) cells.. , 2013, , .		1
98	Survival Following Surgery with or without Adjuvant Chemotherapy for Stage Iâ€“III Non-Small Cell Lung Cancer: An East Asian Population-Based Study. <i>Oncologist</i> , 2012, 17, 1294-1302.	3.7	13
99	The Impact of Diabetes Mellitus on Prognosis of Early Breast Cancer in Asia. <i>Oncologist</i> , 2012, 17, 485-491.	3.7	37
100	Serum Insulin-Like Growth Factor-1 Levels Predict Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy. <i>Clinical Cancer Research</i> , 2012, 18, 3992-3997.	7.0	41
101	Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems. <i>British Journal of Cancer</i> , 2012, 107, 1672-1677.	6.4	24
102	Diabetes Mellitus Is Associated with Increased Mortality in Patients Receiving Curative Therapy for Hepatocellular Carcinoma. <i>Oncologist</i> , 2012, 17, 856-862.	3.7	32
103	Factors Impacting Prognosis Prediction in BCLC Stage C and Child-Pugh Class A Hepatocellular Carcinoma Patients in Prospective Clinical Trials of Systemic Therapy. <i>Oncologist</i> , 2012, 17, 970-977.	3.7	9
104	Survival of Patients with Small Cell Lung Carcinoma in Taiwan. <i>Oncology</i> , 2012, 82, 19-24.	1.9	25
105	Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2012, 82, 59-66.	1.9	29
106	Abstract 4584: $\beta$ -catenin (CTNNB1) and BRAF mutations in advanced hepatocellular carcinoma. , 2012, , .		0
107	Abstract 1904: Transforming growth factor-beta mediated epithelial to mesenchymal transition contributes to in vivo resistance to sorafenib in hepatocellular carcinoma. , 2012, , .		0
108	Dissimilar immunohistochemical expression of ERK and AKT between paired biopsy and hepatectomy tissues of hepatocellular carcinoma. <i>Anticancer Research</i> , 2012, 32, 4865-70.	1.1	11

#	ARTICLE	IF	CITATIONS
109	Increasing Incidence of Brain Metastasis in Patients with Advanced Hepatocellular Carcinoma in the Era of Antiangiogenic Targeted Therapy. <i>Oncologist</i> , 2011, 16, 82-86.	3.7	34
110	High Circulating Endothelial Progenitor Levels Associated with Poor Survival of Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib Combined with Metronomic Chemotherapy. <i>Oncology</i> , 2011, 81, 98-103.	1.9	19
111	Predicting prognosis of patients with advanced hepatocellular carcinoma treated with antiangiogenic therapy using the CUP and CLIP staging systems.. <i>Journal of Clinical Oncology</i> , 2011, 29, e14669-e14669.	1.6	1
112	Abstract 4128: Serum insulin-like growth factor (IGF)-1 levels predict treatment efficacy of anti-angiogenic therapy for patients with advanced hepatocellular carcinoma (HCC)., 2011, , .		0
113	Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma. <i>Anticancer Research</i> , 2011, 31, 4007-11.	1.1	11
114	Pleural metastases as a unique entity with dismal outcome of head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2010, 46, 694-697.	1.5	8
115	Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. <i>Cancer</i> , 2010, 116, 4590-4596.	4.1	154
116	Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010, 6, 80-88.	1.1	27
117	Predictive and Prognostic Values of Tau and ERCC1 in Advanced Breast Cancer Patients Treated with Paclitaxel and Cisplatin. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 286-293.	1.3	27
118	Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2010, 53, 126-131.	3.7	124
119	Characteristics and Risk Factors of Oxaliplatin-related Hypersensitivity Reactions. <i>Journal of the Formosan Medical Association</i> , 2010, 109, 362-368.	1.7	28
120	Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer. <i>Discovery Medicine</i> , 2010, 9, 538-45.	0.5	9
121	Gastric perforation presenting as empyema in a patient with pancreatic cancer on bevacizumab treatment. <i>Anticancer Research</i> , 2009, 29, 1665-7.	1.1	1
122	Fatal thrombocytopenia after oxaliplatin-based chemotherapy. <i>Anticancer Research</i> , 2008, 28, 3115-7.	1.1	25